5-Methoxy-diisopropyltryptamine

5-Methoxy-diisopropyltryptamine

Systematic (IUPAC) name
3-[2-(Diisopropylamino)ethyl]-5-methoxyindole
Clinical data
Pregnancy cat.	?
Legal status	? (UK) Schedule I (US)
Identifiers
CAS number	4021-34-5 N
ATC code	?
PubChem	CID 151182
DrugBank	DB01441
ChemSpider	133247 Y
ChEBI	CHEBI:48282 Y
Chemical data
Formula	C17H26N2O
Mol. mass	274.4
SMILES	eMolecules & PubChem
InChI InChI=1S/C17H26N2O/c1-12(2)19(13(3)4)9-8-14-11-18-17-7-6-15(20-5)10-16(14)17/h6-7,10-13,18H,8-9H2,1-5H3 Y Key:DNBPMBJFRRVTSJ-UHFFFAOYSA-N Y
Physical data
Melt. point	181 °C (358 °F)
N (what is this?)  (verify)

5-MeO-DiPT tablets from Salem, Oregon

5-methoxy-diisopropyltryptamine (5-MeO-DiPT) is a tryptamine psychedelic used as a recreational drug under the street names "foxy" and "foxy methoxy". 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.

Effects

Erowid reports the following effects:

Positive

• Mood lift, euphoria
• Intensification of tactile sensations, smell, etc.
• Sexually interesting
• Emotionally opening
• Diminished aggression, hostility, and jealousy
• Diminished fear, anxiety, and insecurity
• Improved self-confidence
• Substantial enhancement of the appreciation for quality of music
• Increased energy and endurance

Neutral (or positive)

• Out-of-body experience, strong disassociation.
• Feelings of body & muscle energy, buzzing
• Auditory distortions, pitch shifts
• Visual distortions, open and closed-eye patterning, movement trails, shifting colors
• Physical and mental stimulation

Negative

• Possible stomach discomfort, gas & vomiting
• Possible minor jaw-clenching
• Possible Diarrhea
• Anxious stimulation
• Muscle tension / discomfort
• Possible male impotence for duration of drug's effects during higher doses

Pharmacology

The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-DiPT is thought to result primarily from 5-HT_2A receptor agonism, although additional mechanisms of action such as inhibition of monoamine reuptake may be involved also.

Overdosage

Excessive doses have caused clinical intoxication, characterized by nausea, vomiting, agitation, hypotension, mydriasis, tachycardia and hallucinations, in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3–4 hours after an apparent rectal overdose.

Legality

5-MeO-DIPT has been illegal in Germany since September 1999, Greece since February 2003, Denmark since February 2004, Sweden since October 2004, Japan since April 2005, and Singapore since early 2006.

On April 4, 2003, the United States DEA added both 5-MeO-DiPT and AMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.

Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues like DiPT, and DPT neither of which have yet been expressly outlawed in that country. However, in July 2004, Operation Web Tryp was concluded, confirming that U.S. Federal law enforcement intends to prosecute sale of these analogs of 5-MeO-DiPT. Previous prosecutions under the Federal Analog Act have met, on occasion, with failure, given some court rulings regarding possible unconstitutional vagueness regarding what substances are properly considered 'analogs'; such issues may be addressed on appeal.

See also

• 5-MeO-DMT
• 5-MeO-DPT
• 5-MeO-AMT
• 5-MeO-MiPT
• DMT
• DPT
• AMT
• DIPT
• MIPT

External links

• Official Ruling Placing 5-MeO-DIPT into Schedule I
• Erowid information on 5-MeO-DIPT.
• Erowid collection of rulings regarding constitutional and unconstitutional application of the analog act
• 5-MeO-DIPT entry in TiHKAL • info